scholarly journals A Sporadic and Lethal Lassa Fever Case in Forest Guinea, 2019

Viruses ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 1062
Author(s):  
N’Faly Magassouba ◽  
Enogo Koivogui ◽  
Sory Conde ◽  
Moussa Kone ◽  
Michel Koropogui ◽  
...  
Keyword(s):  
Sierra Leone ◽  
Lassa Fever ◽  
Regional Hospital ◽  
Health Centers ◽  
Lassa Virus ◽  
Fever Case ◽  
Internal Bleeding ◽  
Facial Edema ◽  
Frequent Vomiting ◽  
Generation Sequencing

Lassa fever is a rodent-borne disease caused by Lassa virus (LASV). It causes fever, dizziness, vertigo, fatigue, coughing, diarrhea, internal bleeding and facial edema. The disease has been known in Guinea since 1960 but only anectodical acute cases have been reported to date. In January 2019, a 35-year-old man, a wood merchant from Kissidougou, Forest Guinea, presented himself at several health centers with persistent fever, frequent vomiting and joint pain. He was repeatedly treated for severe malaria, and died three weeks later in Mamou regional hospital. Differential diagnosis identified LASV as the cause of death. No secondary cases were reported. The complete LASV genome was obtained using next-generation sequencing. Phylogenetic analysis showed that this strain, namely the Kissidougou strain, belongs to the clade IV circulating in Guinea and Sierra Leone, and is thought to have emerged some 150 years ago. Due to the similarity of symptoms with malaria, Lassa fever is still a disease that is difficult to recognize and that may remain undiagnosed in health centers in Guinea.

scholarly journals Lassa Virus Circulation in Small Mammal Populations in Bo District, Sierra Leone

Biology ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 28
Author(s):  
Umaru Bangura ◽  
Jacob Buanie ◽  
Joyce Lamin ◽  
Christopher Davis ◽  
Gédéon Ngiala Bongo ◽  
...  
Keyword(s):  
Phylogenetic Analysis ◽  
Sierra Leone ◽  
Small Mammal ◽  
Hemorrhagic Fever ◽  
Lassa Fever ◽  
Lassa Virus ◽  
Sierra Leonean ◽  
Bayesian Phylogenetic Analysis ◽  
Prevalent Species ◽  
Lineage Iv

Lassa fever is a viral hemorrhagic fever caused by the Lassa virus LASV, which was first isolated in the rodent Mastomys natalensis in 1974 in Kenema, Sierra Leone. As little is known about the abundance and the presence of LASV in rodents living in the Bo area, we carried out a small mammal longitudinal population survey. A standardized trapping session was performed in various habitats and seasons in six villages over two years (2014–2016) and samples collected were tested for arenavirus IgG and LASV. A Bayesian phylogenetic analysis was performed on sequences identified by PCR. A total of 1490 small mammals were collected, and 16 rodent species were identified, with M. natalensis (355, 24%) found to be the most prevalent species. Forty-one (2.8%) samples were IgG positive, and 31 of these were trapped in homes and 10 in surrounding vegetation. Twenty-nine of 41 seropositive rodents were M. natalensis. We detected four LASV by PCR in two villages, all found in M. natalensis. Phylogenetic analysis showed that the sequences were distributed within the Sierra Leonean clade within lineage IV, distinguishing a Bo sub-clade older than a Kenema sub-clade. Compared to other settings, we found a low abundance of M. natalensis and a low circulation of LASV in rodents in villages around Bo district.

scholarly journals Identification of Common CD8+ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone

2020 ◽  
Vol 94 (12) ◽  
Author(s):  
Saori Sakabe ◽  
Jessica N. Hartnett ◽  
Nhi Ngo ◽  
Augustine Goba ◽  
Mambu Momoh ◽  
...  
Keyword(s):  
T Cell ◽  
West Africa ◽  
Sierra Leone ◽  
T Cell Responses ◽  
Lassa Fever ◽  
Health Concern ◽  
Lassa Virus ◽  
T Cell Epitopes ◽  
Virus Surface ◽  
Cell Responses

ABSTRACT Early and robust T cell responses have been associated with survival from Lassa fever (LF), but the Lassa virus-specific memory responses have not been well characterized. Regions within the virus surface glycoprotein (GPC) and nucleoprotein (NP) are the main targets of the Lassa virus-specific T cell responses, but, to date, only a few T cell epitopes within these proteins have been identified. We identified GPC and NP regions containing T cell epitopes and HLA haplotypes from LF survivors and used predictive HLA-binding algorithms to identify putative epitopes, which were then experimentally tested using autologous survivor samples. We identified 12 CD8-positive (CD8+) T cell epitopes, including epitopes common to both Nigerian and Sierra Leonean survivors. These data should be useful for the identification of dominant Lassa virus-specific T cell responses in Lassa fever survivors and vaccinated individuals as well as for designing vaccines that elicit cell-mediated immunity. IMPORTANCE The high morbidity and mortality associated with clinical cases of Lassa fever, together with the lack of licensed vaccines and limited and partially effective interventions, make Lassa virus (LASV) an important health concern in its regions of endemicity in West Africa. Previous infection with LASV protects from disease after subsequent exposure, providing a framework for designing vaccines to elicit similar protective immunity. Multiple major lineages of LASV circulate in West Africa, and therefore, ideal vaccine candidates should elicit immunity to all lineages. We therefore sought to identify common T cell epitopes between Lassa fever survivors from Sierra Leone and Nigeria, where distinct lineages circulate. We identified three such epitopes derived from highly conserved regions within LASV proteins. In this process, we also identified nine other T cell epitopes. These data should help in the design of an effective pan-LASV vaccine.

scholarly journals Public health response to two imported, epidemiologically related cases of Lassa fever in the Netherlands (ex Sierra Leone), November 2019

2020 ◽  
Vol 25 (15) ◽  
Author(s):  
Femke Overbosch ◽  
Mark de Boer ◽  
Karin Ellen Veldkamp ◽  
Pauline Ellerbroek ◽  
Chantal P Bleeker-Rovers ◽  
...  
Keyword(s):  
Public Health ◽  
The Netherlands ◽  
Sierra Leone ◽  
Healthcare Facility ◽  
Lassa Fever ◽  
Low Risk ◽  
Lassa Virus ◽  
Public Health Response ◽  
Health Response

On 20 November 2019, Lassa fever was diagnosed in a physician repatriated from Sierra Leone to the Netherlands. A second physician with suspected Lassa fever, repatriated a few days later from the same healthcare facility, was confirmed infected with Lassa virus on 21 November. Comprehensive contact monitoring involving high- and low-risk contacts proved to be feasible and follow-up of the contacts did not reveal any case of secondary transmission in the Netherlands.

scholarly journals Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation

mSphere ◽  
2019 ◽  
Vol 4 (5) ◽  
Author(s):  
Junki Maruyama ◽  
John T. Manning ◽  
Elizabeth J. Mateer ◽  
Rachel Sattler ◽  
Natalya Bukreyeva ◽  
...  
Keyword(s):  
Public Health ◽  
Sierra Leone ◽  
Guinea Pigs ◽  
Lassa Fever ◽  
West African ◽  
Lassa Virus ◽  
African Countries ◽  
Successful Development ◽  
Public Health Perspective ◽  
Lethal Infection

ABSTRACT Lassa virus (LASV), a member of the family Arenaviridae, is the causative agent of Lassa fever. Lassa virus is endemic in West African countries, such as Nigeria, Guinea, Liberia, and Sierra Leone, and causes outbreaks annually. Lassa fever onset begins with “flu-like” symptoms and may develop into lethal hemorrhagic disease in severe cases. Although Lassa virus is one of the most alarming pathogens from a public health perspective, there are few licensed vaccines or therapeutics against Lassa fever. The fact that animal models are limited and the fact that mostly laboratory-derived viruses are used for studies limit the successful development of countermeasures. In this study, we demonstrated that the LASV isolate LF2384-NS-DIA-1 (LF2384), which was directly isolated from a serum sample from a fatal human Lassa fever case in the 2012 Sierra Leone outbreak, causes uniformly lethal infection in outbred Hartley guinea pigs without virus-host adaptation. This is the first report of a clinically isolated strain of LASV causing lethal infection in outbred guinea pigs. This novel guinea pig model of Lassa fever may contribute to Lassa fever research and the development of vaccines and therapeutics. IMPORTANCE Lassa virus, the causative agent of Lassa fever, is a zoonotic pathogen causing annual outbreaks in West African countries. Human patients can develop lethal hemorrhagic fever in severe cases. Although Lassa virus is one of the most alarming pathogens from a public health perspective, there are few available countermeasures, such as antiviral drugs or vaccines. Moreover, the fact that animal models are not readily accessible and the fact that mostly laboratory viruses, which have been passaged many times after isolation, are used for studies further limits the successful development of countermeasures. In this study, we demonstrate that a human isolate of Lassa virus causes lethal infection uniformly in Hartley guinea pigs. This novel animal model of Lassa fever may contribute to Lassa fever research and the development of vaccines and therapeutics.

scholarly journals Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Megan L. Heinrich ◽  
Matthew L. Boisen ◽  
Diana K. S. Nelson ◽  
Duane J. Bush ◽  
Robert W. Cross ◽  
...  
Keyword(s):  
Sierra Leone ◽  
Vaccine Development ◽  
Natural Infection ◽  
Development Program ◽  
Lassa Fever ◽  
Cross Reactivity ◽  
Hemorrhagic Disease ◽  
Lassa Virus ◽  
Human Immune System ◽  
Sierra Leonean

Abstract Lassa virus (LASV) is the causative agent of Lassa fever, an often-fatal hemorrhagic disease that is endemic in West Africa. Seven genetically distinct LASV lineages have been identified. As part of CEPI’s (Coalition for Epidemic Preparedness Innovations) Lassa vaccine development program, we assessed the potential of the human immune system to mount cross-reactive and cross-protective humoral immune responses to antigens from the most prevalent LASV lineages, which are lineages II and III in Nigeria and lineage IV in Sierra Leone. IgG and IgM present in the blood of Lassa fever survivors from Nigeria or Sierra Leone exhibited substantial cross-reactivity for binding to LASV nucleoprotein and two engineered (linked and prefusion) versions of the glycoproteins (GP) of lineages II–IV. There was less cross-reactivity for the Zinc protein. Serum or plasma from Nigerian Lassa fever survivors neutralized LASV pseudoviruses expressing lineage II GP better than they neutralized lineage III or IV GP expressing pseudoviruses. Sierra Leonean survivors did not exhibit a lineage bias. Neutralization titres determined using LASV pseudovirus assays showed significant correlation with titres determined by plaque reduction with infectious LASV. These studies provide guidance for comparison of humoral immunity to LASV of distinct lineages following natural infection or immunization.

scholarly journals Review of candidate vaccines for the prevention of Lassa fever

2021 ◽  
Vol 66 (2) ◽  
pp. 91-102
Author(s):  
O. D. Popova ◽  
O. V. Zubkova ◽  
T. A. Ozharovskaia ◽  
D. I. Zrelkin ◽  
D. V. Voronina ◽  
...  
Keyword(s):  
Sierra Leone ◽  
The United States ◽  
Lassa Fever ◽  
West African ◽  
Diagnostic Tools ◽  
Lassa Virus ◽  
African Countries ◽  
Hemorrhagic Fevers ◽  
Imported Cases ◽  
Technological Platforms

The Lassa virus one of the main etiological agent of hemorrhagic fevers in the world: according to WHO estimates, it affects 100,000 to 300,000 people annually, which results in up to 10,000 deaths [1]. Although expansion of Lassa fever caused by this pathogen is mostly limited to the West African countries: Sierra Leone, Liberia, Guinea and Nigeria, imported cases have been historically documented in Europe, the United States of America (USA), Canada, Japan, and Israel [2]. In 2017, WHO included the Lassa virus in the list of priority pathogens in need of accelerated research, development of vaccines, therapeutic agents and diagnostic tools regarding infections they cause [3]. This review describes main technological platforms used for the development of vaccines for the prevention of Lassa fever.

cccccImmunological screening of Lassa Virus among Health workers and Contacts of patients of Lassa fever in Ondo State

Immunobiology ◽  
2021 ◽  
pp. 152076
Author(s):  
Joseph Ojonugwa Shaibu ◽  
Olumuyiwa Babalola Salu ◽  
Olufemi Samuel Amoo ◽  
Ifeoma Idigbe ◽  
Adesola Zaidat Musa ◽  
...  
Keyword(s):  
Health Workers ◽  
Lassa Fever ◽  
Lassa Virus ◽  
Ondo State

Lassa Virus Isolation from Mastomys natalensis Rodents during an Epidemic in Sierra Leone

Science ◽  
1974 ◽  
Vol 185 (4147) ◽  
pp. 263-265 ◽  
Author(s):  
T. P. Monath ◽  
V. F. Newhouse ◽  
G. E. Kemp ◽  
H. W. Setzer ◽  
A. Cacciapuoti
Keyword(s):  
Sierra Leone ◽  
Virus Isolation ◽  
Lassa Virus ◽  
Mastomys Natalensis

scholarly journals Differential pathogenesis of closely related 2018 Nigerian outbreak clade III Lassa virus isolates

2021 ◽  
Vol 17 (10) ◽  
pp. e1009966
Author(s):  
Derek R. Stein ◽  
Bryce M. Warner ◽  
Jonathan Audet ◽  
Geoff Soule ◽  
Vinayakumar Siragam ◽  
...  
Keyword(s):  
Animal Models ◽  
Lassa Fever ◽  
Geographic Region ◽  
World Health ◽  
Limiting Factor ◽  
Lassa Virus ◽  
African Countries ◽  
Animal Models Of Disease ◽  
Medical Countermeasures

Nigeria continues to experience ever increasing annual outbreaks of Lassa fever (LF). The World Health Organization has recently declared Lassa virus (LASV) as a priority pathogen for accelerated research leading to a renewed international effort to develop relevant animal models of disease and effective countermeasures to reduce LF morbidity and mortality in endemic West African countries. A limiting factor in evaluating medical countermeasures against LF is a lack of well characterized animal models outside of those based on infection with LASV strain Josiah originating form Sierra Leone, circa 1976. Here we genetically characterize five recent LASV isolates collected from the 2018 outbreak in Nigeria. Three isolates were further evaluated in vivo and despite being closely related and from the same spatial / geographic region of Nigeria, only one of the three isolates proved lethal in strain 13 guinea pigs and non-human primates (NHP). Additionally, this isolate exhibited atypical pathogenesis characteristics in the NHP model, most notably respiratory failure, not commonly described in hemorrhagic cases of LF. These results suggest that there is considerable phenotypic heterogeneity in LASV infections in Nigeria, which leads to a multitude of pathogenesis characteristics that could account for differences between subclinical and lethal LF infections. Most importantly, the development of disease models using currently circulating LASV strains in West Africa are critical for the evaluation of potential vaccines and medical countermeasures.

Sign in / Sign up

Export Citation Format

Share Document